Modus Therapeutics Completes a SEK 140 Million Financing led by HealthCapFunds to be used to continue the clinical development of sevuparin for sickle cell disease STOCKHOLM, July 13, 2018-- Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that it has raised SEK 140 million in a financing led by new investor HealthCap. HealthCap is a European venture capital firm with a focus on investments in breakthrough therapies of diseases with highly unmet medical needs.